Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Fredun Pharmaceuticals targets a blended growth rate of approximately 30%-35% year-on-year over the next 3 years, combining growth from new age brands and vintage business. Fredun expects blended revenue growth of around 30% to 35% year-on-year over the next 3 years, driven by both new age brands (35%-45% growth) and vintage business (15%-20% growth).
From Fredun Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Fredun Pharmaceuticals targets a blended growth rate of approximately 30%-35% year-on-year over the next 3 years, combining growth from new age brands and vintage business.
- The pet care segment (~INR40-45 crore currently) aims for 40%-50% year-on-year growth for the next 3-4 years, with further acceleration expected once cat food and diagnostics revenues start contributing.
- Functional foods sales are expected to grow rapidly, with INR18-24 crore targeted this year alone and cat food launch planned by Q3/Q4 FY27.
- GX (generic pharmaceuticals) division projects 25%-35% growth annually over the next 5 years, expanding presence from 19 states with a currently small base (~INR100-110 crore).
2 more points from Fredun Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals plans significant capital expenditure (CapEx) to expand manufacturing capacity.
- Target is to have one of the largest manufacturing units at a single location in the country by end of December 2028/early 2029.
- CapEx planned for FY27 is around INR 30 to 40 crores.
- Similar CapEx budget of INR 30 to 40 crores is expected for the following year as well.
- Maintenance CapEx is estimated at around 2% of revenue (~INR 20 crores at INR 1000 crore revenue) to upgrade facilities and comply with cGMP regulations.
2 more points from Fredun Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals mentioned a boost in Q1 FY27 sales partly due to booking additional orders in the last quarter of the previous year.
- They offered customers better pricing, encouraging them to book further orders, which contributed to a higher order book.
- The management expects growth to continue at similar levels in coming quarters, indicating a healthy and active order pipeline.
- The company focuses on consistency in product availability and new product introductions to maintain order momentum.
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fredun Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q1 FY27 results?
Fredun Pharmaceuticals targets a blended growth rate of approximately 30%-35% year-on-year over the next 3 years, combining growth from new age brands and vintage business. Fredun expects blended revenue growth of around 30% to 35% year-on-year over the next 3 years, driven by both new age brands (35%-45% growth) and vintage business (15%-20% growth).
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.4 with a market cap of ₹2,373 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals plans significant capital expenditure (CapEx) to expand manufacturing capacity. - Target is to have one of the largest manufacturing units at a single location in the country by end of December 2028/early 2029. - CapEx planned for FY27 is around INR 30 to 40 crores. - Similar CapEx budget of INR 30 to 40 crores is expected for the following year as well. - Maintenance CapEx is estimated at around 2% of revenue (~INR 20 crores at INR 1000 crore revenue) to upgrade facilities and comply with cGMP regulations. - Strategic acquisitions are also planned in the pet care segment, with some being small and some big, all fundamental to the long-term growth story.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.